Home › Targets › EGFR
EGFR (8 companies · 12 programs)
Companies with an active program directed at EGFR.
- ficerafusp alfa — Head and Neck Squamous Cell Carcinoma Phase 2
- ficerafusp alfa — Colorectal Cancer Phase 1
- ficerafusp alfa — Cutaneous Squamous Cell Carcinoma Phase 1
- ficerafusp alfa — Anal Squamous Cell Carcinoma Phase 1
- silevertinib — Non-Small Cell Lung Cancer Phase 2
- silevertinib — Glioblastoma Phase 2
- firmonertinib — Non-Small Cell Lung Cancer Phase 3
- zipalertinib — Non-Small Cell Lung Cancer NDA Submitted
- enozertinib — Non-Small Cell Lung Cancer Phase 1
- SNDX-4321 — Non-Small Cell Lung Cancer Preclinical
- VIR-5525 — Solid Tumors Phase 1